KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Equity (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Return on Equity for 10 consecutive years, with 0.32% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 11.0% to 0.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.32% through Dec 2025, down 11.0% year-over-year, with the annual reading at 0.32% for FY2025, 10.0% down from the prior year.
  • Return on Equity hit 0.32% in Q4 2025 for CRISPR Therapeutics AG, down from 0.29% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.36% in Q2 2021 to a low of 0.52% in Q3 2022.
  • Historically, Return on Equity has averaged 0.16% across 5 years, with a median of 0.21% in 2023.
  • Biggest five-year swings in Return on Equity: skyrocketed 49bps in 2021 and later crashed -83bps in 2022.
  • Year by year, Return on Equity stood at 0.0% in 2021, then crashed by -18944bps to 0.34% in 2022, then soared by 75bps to 0.09% in 2023, then tumbled by -148bps to 0.21% in 2024, then tumbled by -52bps to 0.32% in 2025.
  • Business Quant data shows Return on Equity for CRSP at 0.32% in Q4 2025, 0.29% in Q3 2025, and 0.29% in Q2 2025.